On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

UPDATED: A patient in Akashi's suspended Duchenne MD trial dies

A little more than a week after Cambridge, MA-based Akashi Therapeutics suspended its study of a new drug for Duchenne muscular dystrophy after a patient was sent to the hospital, the biotech reports that the trial subject has died.

Spotlight On... Gates Foundation backs Affinivax's Prevnar 13 rival; FDA rejects Vertex's latest Kalydeco app; and much more...

Cambridge, MA's Affinivax secured another $2.5 million in funding from the Bill and Melinda Gates Foundation to support its work on a pneumococcal vaccine that can best Pfizer's top-selling...

Silk Therapeutics Raises $6 Million In Series A2 Financing

MEDFORD, Mass., Feb. 3, 2016 /PRNewswire/ -- Silk Therapeutics, Inc., today announced the closing of a $6 million Series A2 financing round. Silk Therapeutics has now raised a total of $10.25 million...

Celltrion's take on J&J's Remicade is 'highly similar' to the original, FDA says

FDA staff signaled support for Celltrion's biosimilar of Johnson & Johnson's Remicade in documents released ahead of a key panel vote, a positive development for the South Korean company as it works with Pfizer to tap the U.S. market.

Erin O'Shea Named New HHMI President

Highlights Erin O'Shea is a leader in the fields of gene regulation, signal transduction, and systems biology. She was named HHMI's vice president and chief scientific officer in 2013. ...

Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 1, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the promotion of Katie Watson to Executive Vice President, Human Resources. Ms. Watson joined...

U.S. FDA Acknowledges Receipt of Resubmission of Shire's New Drug Application for Lifitegrast for Dry Eye Disease in Adults

LEXINGTON, Massachusetts, February 4, 2016 /PRNewswire/ -- - New FDA action date of July 22, 2016 - Lifitegrast has the potential to be the only product approved in the U.S. in the past decade...

Osiris Therapeutics Announces Leadership Transition

February 03, 2016 04:30 PM Eastern Standard Time COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing...

Shire's self-described blockbuster eye drug lines up for FDA do-over

Shire's once-rejected treatment for dry eye disease has another date with the FDA, supported by new data the company believes will get the drug on the market and eventually help bring in more than $1 billion in annual revenue.

'